Abstract 130P
Background
The p53 protein is a transcription factor that preserves the integrity of the genome and activates downstream genes the products of which are involved in cell cycle arrest, apoptosis, and DNA repair. The TP53 gene is the most frequently mutated gene in human cancer. Missense mutations in the DNA-binding domain lead to protein destabilization and denaturation. This results in impaired transcriptional activity, uncontrolled proliferation, inhibition of apoptosis, and resistance to anticancer therapies. Reactivation of mutant p53 protein using small molecules is a highly promising strategy for therapeutic treatment of cancer. In this work we aimed to evaluate the effectiveness of indazole derivatives as modulators of p53R248W, p53R273H, and p53R248Q mutants.
Methods
SNB-19 p53R273H, MiaPaca-2 p53R248W, Ovcar-3 p53R248Q, and A549 p53wt cells were treated with compounds in the concentration range of 0-200 μM. The cytotoxicity of the compound was assessed using colorimetric MTS assay. The data were processed in the GraphPad Prism: the dependence of cell viability (%) on the logarithm of the compound concentrations was plotted. The p53 and p21 expression levels were evaluated using immunoblotting.
Results
IC50 values for the compounds could only be determined for p53-mutated cell lines at a concentration range of 40-150 μM. The expression levels of p53 protein in the same cell lines were also higher than in A549 (wild-type cell line), as evidenced by the results of immunoblotting analysis. We also observed increase in p21 protein levels upon treatment with the compounds.
Conclusions
The results showed that the compounds exhibit a specific effect on p53 mutant cell lines, and lead to increased expression of p53 target proteins associated with cell cycle arrest. The work was funded by the RSF grant 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Legal entity responsible for the study
The authors.
Funding
The work was funded by the RSF grant 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract